[ORGANIZATION]
Dupixent
Featured in 3 tracked stories · first seen
Situations
Regeneron and Sanofi Q2 2026 financial performance
2 clusters · 2 sources · last updated
Latest: Sanofi reports strong Q2 2026 revenue growth driven by Dupixent
In the second quarter of 2026, both Regeneron Pharmaceuticals and Sanofi reported strong financial growth, largely attributed to the performance of the immunology drug Dupixent. Regeneron reported revenue of $4.29 billi
Also covered in
-
Sanofi Raises 2026 Revenue Target After Strong Mid‑Year Results
[BUSINESS] · 5 sources ·